Sunitinib l malate

Sunitinib L-malate (LC Laboratories, Woburn, MA) was dissolved in hydrochloric acid (1.0 molar ratio of sunitinib), polysorbate 80 (0.5%; Sigma-Aldrich, Schnelldorf, Germany), polyethylene glycol 300 (10%; Sigma-Aldrich), sodium hydroxide (to adjust pH to 3.5), and sterile water. Mice were treated with 40 mg/kg/day sunitinib or vehicle for 4 days by oral administration.

Bevacizumab (Avastin; Hoffman-La Roche, Basel, Switzerland) was dissolved in physiological saline and administered by intraperitoneal injection. The injection volume varied with the mouse weight and was 0.25 ml for a 25-g mouse. Tumor-bearing mice were treated with 3 bevacizumab doses of 10 mg/kg or vehicle over a period of 8 days.
sunitinib l-malate (LC Laboratories, Woburn, MA, USA) was dissolved in hydrochloric acid (1.0 molar ratio of sunitinib). Polysorbate 80 (0.5%; Sigma-Aldrich, Schnelldorf, Germany), polyethylene glycol 300 (10%; Sigma Aldrich), sodium hydroxide to adjust to a pH of 3.5, and sterile water were added to the solution. Tumor-bearing mice were treated with 4 sunitinib doses of 40 mg/kg or vehicle over a period 4 days. sunitinib and vehicle were administered orally in volumes of ~0.2 ml by using a gavage.
Treatment effects were evaluated by DW-MRI and/or immunohistochemistry. The DW-MRI was conducted 3 days after the last bevacizumab dose or 1 day after the last sunitinib dose, and the tumors were resected for immunohistochemical examinations shortly after the DW-MRI.